E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Von Willebrand's disease (VWD) |
|
E.1.1.1 | Medical condition in easily understood language |
Von Willebrand's disease (VWD) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10047715 |
E.1.2 | Term | Von Willebrand's disease |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are to evaluate the:
• Efficacy and
• Safety
of Biostate® in the treatment of non-surgery bleeds, in the management of surgery procedures and prophylactic therapy in patients with VWD where
1-deamino-8-D-arginine vasopressin/Desmopressin (DDAVP) treatment is deemed by the Investigator to be ineffective, inadequate, or contraindicated.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients who fulfill the following criteria are eligible for inclusion into this study:
a) Patients with a diagnosis VWD who require prophylactic therapy, have a non-surgery bleed, or are undergoing surgery.
b) Patients who would routinely receive a plasma derived FVIII/VWF product as treatment for their VWD.
c) Patients over 3 years of age and ≥14 kg.
Inclusion of children < 13 years of age into the surgical and non-surgical bleed arms of the study will be at the discretion of the Investigator. The Investigator will take into consideration the blood profile of the patient and the required blood draw volume, bearing in mind that 17 ml of blood
is to be drawn prior to each administration of Biostate® and that in accordance with the National Institute of Health Clinical Centre Guidelines, a paediatric blood draw should not exceed 3ml/kg, or 7ml/kg in a 6 week period.
d) Patients and/or their legally acceptable representative must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements.
In addition, patients receiving prophylactic therapy or being managed for elective surgery must also fulfill the following criterion:
e) Patients must have been vaccinated against hepatitis A and B (unless protective antibodies are present resulting from a previously experienced infection). Documentation of immunisation (or protective antibodies resulting from a previous infection) must be present at baseline.
|
|
E.4 | Principal exclusion criteria |
The following patients are not eligible for inclusion into this study:
a) Patients with a known history of adverse drug reactions to factor VIII/VWF concentrates.
b) Patients with a known or suspected VWF or FVIII inhibitor.
c) Patients who are currently taking non-steroidal anti-inflammatory drugs (NSAIDs) which in the opinion of the Investigator would affect the efficacy and safety outcomes of the study.
d) Patients with evidence or a history within the previous 12 months of abuse of any drug substance, licit or illicit, which in the opinion of the Investigator may affect the ability of the patient to comply with all protocol requirements.
e) Patients who have within 90 days prior to the study screening visit, participated in a clinical study or used an investigational compound (eg. a new chemical entity not registered for clinical use), or who are planning to enter such a different study during the study period.
f) Patients who are suffering from an acute or chronic medical condition, other than VWD, which may, in the opinion of the Investigator, affect the conduct of the study.
g) Patients with a positive pregnancy test.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy Endpoints:
• Assessment of haemostatic efficacy using a grading scale of excellent, good, moderate and none.
• For non-surgery bleed/surgery procedures:
- The plasma levels of FVIII:C, VWF:RCo, VWF:Ag and VWF:CB.
- Blood transfusion requirements.
- FVIII:C and VWF:RCo in IU/kg (per treatment) required to resolve the event.
- The number of treatments required until resolution of the event.
- Assessment of blood loss during any surgery procedures.
• For prophylaxis therapy:
- FVIII:C IU/kg and VWF:RCo IU/kg per month.
- Number of spontaneous bleeding events.
Safety Endpoints:
• The nature and incidence of AEs.
• The development of inhibitors to FVIII.
• The use of concomitant medications. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |